Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Clinical Post-Transplant Lymphoproliferative Disorders Publisher Pubmed



Aghsaeifard Z1 ; Alizadeh R2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Anesthesiology and Intensive Care, School of Medicine, AJA University of Medical Sciences, Tehran, Iran

Source: Cardiovascular and Hematological Disorders - Drug Targets Published:2022


Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are characterized by hyperprolife-ration of B cells due to solid organ or allogeneic hematopoietic stem cell transplant. Based on histological findings, it is divided into 4 categories. Most PTLD patients are Epstein–Barr virus (EBV) positive. Additionally, aggressive immunosuppressive therapies can also lead to PTLD. Reducing immunosuppressive regimes, antivirals, monoclonal antibodies, chemotherapy, and radiotherapy are available therapeutic options, depending on the nature and phase of the disease. This review briefly highlights pathogenesis, risk factors, prevention, and therapeutic strategies regarding PTLDs. © 2022 Bentham Science Publishers.
Other Related Docs
10. Atrial Fibrillation and Ventricular Tachyarrhythmias: Advancements for Better Outcomes, Cardiovascular and Hematological Disorders - Drug Targets (2020)